Cloning of Novel Soluble Gp130 and Detection of Its Neutralizing Autoantibodies in Rheumatoid Arthritis

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2000 Jul 6

PMID 10880057

Citations 26

Authors

M Tanaka

M Kishimura

S Ozaki

F Osakada

H Hashimoto

M Okubo

M Murakami

K Nakao

Affiliations

Soon will be listed here.

Abstract

In an attempt to isolate disease-associated autoantigens in rheumatoid arthritis (RA), we cloned a new autoantigen named gp130-RAPS, which is a novel soluble form of the IL-6 signal-transducing molecule gp130. gp130-RAPS is a 50-kDa protein translated from alternatively spliced mRNA and has a truncated form of gp130 with a unique sequence, Asn-Ile-Ala-Ser-Phe (NIASF), in its COOH-terminus. We observed serum antibodies to this NIASF sequence frequently in patients with RA, but not in those with other systemic rheumatic diseases or in healthy subjects. In RA, detection of those antibodies was significantly associated with disease activity indices such as serum C-reactive protein (CRP) levels, erythrocyte sedimentation rate, blood platelet counts, and serum IL-6 concentration. In vitro experiments revealed that gp130-RAPS inhibited IL-6 activity, and this inhibition was neutralized by antibodies to the COOH-terminus of gp130-RAPS derived from patients with RA. Thus, autoantibody to gp130-RAPS may play an important role in the progression of RA by promoting IL-6 activity. Inspection of autoantibodies to gp130-RAPS may become a practical clinical test for RA. gp130-RAPS and its autoantibody provide a new clue to the complicated pathogenesis of RA.

Citing Articles

Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.

Gupta D, Orehek S, Turunen J, ODonovan L, Gait M, El-Andaloussi S Cells. 2023; 12(18).

PMID: 37759507 PMC: 10526877. DOI: 10.3390/cells12182285.

IL-6 signaling in acute exercise and chronic training: Potential consequences for health and athletic performance.

Nash D, Hughes M, Butcher L, Aicheler R, Smith P, Cullen T Scand J Med Sci Sports. 2022; 33(1):4-19.

PMID: 36168944 PMC: 10092579. DOI: 10.1111/sms.14241.

An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.

Wang J, Zhang W, Roehrl V, Roehrl M, Roehrl M Front Immunol. 2022; 13:831849.

PMID: 35401574 PMC: 8987778. DOI: 10.3389/fimmu.2022.831849.

Characteristics of Interleukin-6 Signaling in Elective Cardiac Surgery-A Prospective Cohort Study.

Puchinger J, Ryz S, Nixdorf L, Edlinger-Stanger M, Lassnigg A, Wiedemann D J Clin Med. 2022; 11(3).

PMID: 35160042 PMC: 8836792. DOI: 10.3390/jcm11030590.

Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the - Gene Region in Immature Dendritic Cells.

Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Diez Garcia J, Villanueva Etxebarria A Front Immunol. 2022; 12:816930.

PMID: 35111166 PMC: 8801523. DOI: 10.3389/fimmu.2021.816930.

References

Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T . Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol. 1998; 20(1-2):247-59. DOI: 10.1007/BF00832010. View

Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H . Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987; 84(20):7251-5. PMC: 299269. DOI: 10.1073/pnas.84.20.7251. View

Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y . Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993; 82(4):1120-6. View

Diamant M, Rieneck K, Mechti N, Zhang X, Svenson M, Bendtzen K . Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin-6 signal transducer gp130. FEBS Lett. 1997; 412(2):379-84. DOI: 10.1016/s0014-5793(97)00750-3. View

Gearing D, Comeau M, Friend D, Gimpel S, Thut C, McGourty J . The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992; 255(5050):1434-7. DOI: 10.1126/science.1542794. View

Yin T, Taga T, Tsang M, Yasukawa K, Kishimoto T, Yang Y . Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol. 1993; 151(5):2555-61. View

Mimori T, Suganuma K, TANAMI Y, Nojima T, Matsumura M, Fujii T . Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci U S A. 1995; 92(16):7267-71. PMC: 41320. DOI: 10.1073/pnas.92.16.7267. View

Ip N, Nye S, Boulton T, Davis S, Taga T, Li Y . CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 1992; 69(7):1121-32. DOI: 10.1016/0092-8674(92)90634-o. View

Zhang J, Zhang Y, Owczarek C, Ward L, Moritz R, Simpson R . Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. J Biol Chem. 1998; 273(17):10798-805. DOI: 10.1074/jbc.273.17.10798. View

10.

Kotake S, Sato K, Kim K, Takahashi N, Udagawa N, Nakamura I . Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996; 11(1):88-95. DOI: 10.1002/jbmr.5650110113. View

11.

Taga T, Narazaki M, Yasukawa K, Saito T, Miki D, Hamaguchi M . Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A. 1992; 89(22):10998-1001. PMC: 50470. DOI: 10.1073/pnas.89.22.10998. View

12.

Despres N, Talbot G, Plouffe B, Boire G, Menard H . Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest. 1995; 95(4):1891-6. PMC: 295733. DOI: 10.1172/JCI117870. View

13.

Matsuda T, Hirano T, Kishimoto T . Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur J Immunol. 1988; 18(6):951-6. DOI: 10.1002/eji.1830180618. View

14.

Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T . Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J Immunol. 1992; 148(12):4066-71. View

15.

Mihara M, Moriya Y, Kishimoto T, Ohsugi Y . Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995; 34(4):321-5. DOI: 10.1093/rheumatology/34.4.321. View

16.

Wendling D, Racadot E, Wijdenes J . Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993; 20(2):259-62. View

17.

Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T . Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990; 63(6):1149-57. DOI: 10.1016/0092-8674(90)90411-7. View

18.

Sternberg E, Hill J, Chrousos G, Kamilaris T, Listwak S, Gold P . Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A. 1989; 86(7):2374-8. PMC: 286915. DOI: 10.1073/pnas.86.7.2374. View

19.

Spring D, KREBS E . Deletion of 11 amino acids in p90(rsk-mo-1) abolishes kinase activity. Mol Cell Biol. 1998; 19(1):317-20. PMC: 83889. DOI: 10.1128/MCB.19.1.317. View

20.

Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T . Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989; 58(3):573-81. DOI: 10.1016/0092-8674(89)90438-8. View